Midlife and Late-Life Alzheimer Disease Blood Biomarkers and 11-Year Cognitive Decline.
Blood proteins in late life predict cognitive decline patterns, offering hope for early identification of those at highest dementia risk.
This observational cohort study examined Midlife and Late-Life Alzheimer Disease Blood Biomarkers and 11-Year Cognitive Decline. The PubMed abstract reports that In late-life, biomarkers for AD, neurodegeneration, and neuroinflammation were associated with faster decline across different cognitive domains, but associations remained strongest for p-tau181 and memory.
What the study was
- Study design
- Observational cohort study
- Population
- individuals from ARIC field centers (Jackson, Mississippi
- Sample size
- 920
- Category
- Prevention
- Maturity
- Validated
- Journal
- Neurology
Why it surfaced
Score 5/10 reflects observational cohort study evidence with abstract only access; genuine match to Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.